CN113453690A - 用于抗衰老的三联疗法 - Google Patents

用于抗衰老的三联疗法 Download PDF

Info

Publication number
CN113453690A
CN113453690A CN201980091563.7A CN201980091563A CN113453690A CN 113453690 A CN113453690 A CN 113453690A CN 201980091563 A CN201980091563 A CN 201980091563A CN 113453690 A CN113453690 A CN 113453690A
Authority
CN
China
Prior art keywords
therapeutic agent
mitochondrial
doxycycline
vitamin
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980091563.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·P·利桑蒂
F·苏特加
M·菲奥里罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lunela Biotechnology Co ltd
Original Assignee
Lunela Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunela Biotechnology Co ltd filed Critical Lunela Biotechnology Co ltd
Publication of CN113453690A publication Critical patent/CN113453690A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980091563.7A 2018-12-17 2019-12-16 用于抗衰老的三联疗法 Pending CN113453690A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862780488P 2018-12-17 2018-12-17
US62/780,488 2018-12-17
US201962804411P 2019-02-12 2019-02-12
US62/804,411 2019-02-12
US201962834794P 2019-04-16 2019-04-16
US62/834,794 2019-04-16
PCT/US2019/066553 WO2020131704A1 (en) 2018-12-17 2019-12-16 Triple combination therapies for anti-aging

Publications (1)

Publication Number Publication Date
CN113453690A true CN113453690A (zh) 2021-09-28

Family

ID=71102298

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980091563.7A Pending CN113453690A (zh) 2018-12-17 2019-12-16 用于抗衰老的三联疗法

Country Status (20)

Country Link
US (2) US11918597B2 (enExample)
EP (1) EP3897659A4 (enExample)
JP (1) JP7641897B2 (enExample)
KR (1) KR20210104830A (enExample)
CN (1) CN113453690A (enExample)
AU (1) AU2019402099B2 (enExample)
BR (1) BR112021011964A2 (enExample)
CA (1) CA3123850A1 (enExample)
CL (1) CL2021001617A1 (enExample)
CO (1) CO2021009008A2 (enExample)
CR (1) CR20210351A (enExample)
DO (1) DOP2021000123A (enExample)
EC (1) ECSP21052757A (enExample)
IL (1) IL284059B2 (enExample)
MX (1) MX2021007347A (enExample)
PE (1) PE20220499A1 (enExample)
PH (1) PH12021551435A1 (enExample)
SG (1) SG11202106532WA (enExample)
WO (1) WO2020131704A1 (enExample)
ZA (1) ZA202104254B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115551827A (zh) * 2020-05-13 2022-12-30 卢内拉生物技术有限公司 靶向癌症干细胞和防止转移的9-氨基-多西环素肉豆蔻酰衍生物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210072026A (ko) 2018-10-02 2021-06-16 루넬라 바이오테크 인코포레이티드 세놀리틱 약물로서 아지트로마이신 및 록시스로마이신 유도체
EP3923941B1 (en) 2019-02-12 2025-12-03 Novartis AG Pharmaceutical combination comprising tno155 and ribociclib
WO2025114970A1 (en) * 2023-11-30 2025-06-05 Lunella Biotech, Inc. Senolytic compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170109A1 (en) * 2017-03-15 2018-09-20 Lunella Biotech, Inc. Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
WO2018195434A1 (en) * 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018213751A1 (en) * 2017-05-19 2018-11-22 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149776C (da) * 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
US6805880B1 (en) * 1999-08-20 2004-10-19 Ferrosan A/S Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
RU2223103C1 (ru) * 2002-07-17 2004-02-10 Открытое акционерное общество "Биосинтез" Фармацевтическая композиция, обладающая антибактериальным действием
CN1837229A (zh) * 2005-08-05 2006-09-27 济南思创生物技术有限公司 克拉霉素衍生物及其制备方法和药物应用
US7282225B1 (en) * 2006-09-27 2007-10-16 Occular Technologies, Inc. Composition and methods for improving retinal health
US8168597B2 (en) * 2008-10-22 2012-05-01 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
WO2012112945A1 (en) * 2011-02-18 2012-08-23 The Trustees Of Columbia University In The City Of New York Use of matrix metalloproteinase inhibitors to treat tuberculosis
WO2013024467A2 (en) 2011-08-18 2013-02-21 Ecole Polytechnique Federale De Lausanne (Epfl) Mitochondrial ribosomal proteins as aging regulators
US9775855B2 (en) * 2011-09-14 2017-10-03 Thomas J. Lewis Compositions comprising macrolide and tetracycline and their uses
GB201217310D0 (en) * 2012-09-27 2012-11-14 C10 Pharma As Compounds
CN103536530A (zh) * 2013-10-30 2014-01-29 王玉万 盐酸多西环素长效注射剂及制备方法
WO2018193116A1 (en) * 2017-04-20 2018-10-25 Novintum Biotechnology Gmbh Azithromycin derivatives containing a phosphonium ion as anticancer agents
US11883497B2 (en) * 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
KR20210072026A (ko) * 2018-10-02 2021-06-16 루넬라 바이오테크 인코포레이티드 세놀리틱 약물로서 아지트로마이신 및 록시스로마이신 유도체
AU2019403048B2 (en) * 2018-12-17 2025-01-23 Lunella Biotech, Inc. Triple combination therapies for targeting mitochondria and killing cancer stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170109A1 (en) * 2017-03-15 2018-09-20 Lunella Biotech, Inc. Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
WO2018195434A1 (en) * 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018213751A1 (en) * 2017-05-19 2018-11-22 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115551827A (zh) * 2020-05-13 2022-12-30 卢内拉生物技术有限公司 靶向癌症干细胞和防止转移的9-氨基-多西环素肉豆蔻酰衍生物

Also Published As

Publication number Publication date
CA3123850A1 (en) 2020-06-25
PH12021551435A1 (en) 2021-12-06
ECSP21052757A (es) 2021-08-31
US20240316086A1 (en) 2024-09-26
CO2021009008A2 (es) 2021-10-20
AU2019402099B2 (en) 2025-01-23
JP2022514739A (ja) 2022-02-15
MX2021007347A (es) 2021-07-15
ZA202104254B (en) 2023-01-25
EP3897659A4 (en) 2022-09-07
JP7641897B2 (ja) 2025-03-07
IL284059B2 (en) 2023-08-01
WO2020131704A8 (en) 2021-07-29
WO2020131704A1 (en) 2020-06-25
DOP2021000123A (es) 2021-08-15
IL284059A (en) 2021-08-31
CR20210351A (es) 2021-07-14
SG11202106532WA (en) 2021-07-29
US20220016151A1 (en) 2022-01-20
CL2021001617A1 (es) 2022-01-14
EP3897659A1 (en) 2021-10-27
BR112021011964A2 (pt) 2021-09-08
US11918597B2 (en) 2024-03-05
AU2019402099A1 (en) 2021-07-08
PE20220499A1 (es) 2022-04-07
IL284059B1 (en) 2023-04-01
KR20210104830A (ko) 2021-08-25

Similar Documents

Publication Publication Date Title
JP7487205B2 (ja) ミトコンドリアを標的化し癌幹細胞を死滅させるための三剤併用療法
US20240316086A1 (en) Triple combination therapies for anti-aging
Liu et al. Mannose-conjugated platinum complexes reveals effective tumor targeting mediated by glucose transporter 1
EP3934631B1 (en) Carotenoids in the treatment of senescence-related diseases
WO2017162108A1 (zh) 一种柱芳烃类复合物、其制备方法、药物组合物和用途
JPH08502488A (ja) 前立腺癌および初期神経悪性疾患に対するベンゾキノイドアンサマイシンの殺腫瘍活性
MX2007010492A (es) Compuestos que tienen propiedades anticancer.
JP2009531301A (ja) 癌治療のためのヘキソース化合物
Upadhyay et al. Methyl-β-cyclodextrin enhances the susceptibility of human breast cancer cells to carboplatin and 5-fluorouracil: Involvement of Akt, NF-κB and Bcl-2
Doncel-Pérez et al. Synthetic glycolipids for glioma growth inhibition developed from neurostatin and NF115 compound
AU2020255063B2 (en) Combined use of A-nor-5α androstane compound drug and anticancer drug
US20060100274A1 (en) Therapeutic avenanthramide compounds
US11827588B2 (en) Compound, agent and composition for the suppression of cancer growth
US20230255961A1 (en) Rotomeric Isomers of 4-Alkyl-5-Heteroaryl-3H-1,2-Dithiole-3-Thiones
BR112024024446B1 (pt) Compostos macrolídeos senolíticos, composição farmacêutica e seus usos
HK40084622A (en) Use of carotenoids in the treatment of senescence-related diseases
JP2024506999A (ja) がんを処置するための組成物および方法
DE102015009609B4 (de) Glykostimulatorische Therapie von Krebs und Metastasen: Biologisch-metabolische Krebsabwehr
Sirisangtragul Pharmacokinetics and pharmacodynamics of intraventricularly administered etoposide in brain tumour patients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210928